With Evotec’s state-of-the-art integrated autopurification and analytical platforms each compound will be of the highest purity to deliver high quality results in Almirall’s pharmaceutical screening and medicinal chemistry programs.
“We are confident that our proprietary templates and innovative approaches in creating novel molecules will quickly deliver drug-like compounds to support our partner in their discovery of new drugs,” commented Dr Mark Ashton, executive vice president of business development services at Evotec.
“In the process of selecting the right partner for our ambitious library project, we were impressed by Evotec’s reputation and the company’s impressive track record in designing and delivering diverse and focused compound libraries,” said Dr Jose Ma Palacios, General Director for R&D at Almirall.